Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
GI 254023X: ADAM10 Inhibitor Workflow Guide
2026-09-30
GI 254023X enables selective ADAM10 inhibition for dissecting Notch1 signaling, Jurkat-cell phenotypes, and endothelial barrier protection. This guide translates product specifications and a quantitative assay-design lesson from neuronal research into practical workflows with controls, optimization steps, and troubleshooting.
-
Vancomycin Hydrochloride: From Target to Assay
2026-09-30
Explore how Vancomycin hydrochloride connects molecular target engagement with bacterial susceptibility testing, resistance interpretation, and translational infection models. This guide adds an evidence-based assay framework beyond routine workflow protocols.
-
N-octanoyl-L-Homoserine lactone Workflows
2026-09-29
Use N-octanoyl-L-Homoserine lactone as a defined C8-HSL stimulus to connect quorum sensing with biofilm phenotypes, virulence signaling, and host-cell responses. This guide combines concentration-controlled assays, pathway-resolved cancer models, and practical troubleshooting for infection biology research.
-
Farnesyl Alcohol Azide: KRAS Biology Guide
2026-09-29
Farnesyl Alcohol Azide is a C4380 product whose supplied dossier does not include a structure, purity, or validated assay protocol. A 2026 Cell study links KRAS farnesylation at C185 to liquid-liquid phase separation, RCE1 clustering, colon tumor growth, and altered response to KRAS G12C inhibition, but it does not establish that C4380 produces these effects.
-
WM-8014: Time-Gated Epigenetic Assay Design
2026-09-28
WM-8014 is a reversible KAT6A inhibitor for separating target engagement, cell-cycle arrest, and senescence in complex cancer models. This guide connects its mechanism to time-gated CRISPR logic and practical assay design for cancer biology research.
-
Octanoic Acid-Rich Enteral Nutrition in IBD
2026-09-28
A 2025 study reports that octanoic acid-rich enteral nutrition alleviated experimental inflammatory bowel disease while shifting intestinal macrophage polarization through a PPARγ/STAT-1/STAT-6 signaling axis. Intervention experiments and macrophage cell studies support a functional role for this pathway, although the findings remain preclinical and do not establish clinical efficacy.
-
Direct Mouse Genotyping Kit Plus for EP4 Studies
2026-09-27
A purification-free lysate workflow can simplify routine mouse genotyping for macrophage and atherosclerosis studies. Learn how to use the Direct Mouse Genotyping Kit Plus in allele-screening workflows, interpret its role in the EP4 research context, and troubleshoot common PCR issues without confusing genotyping with phenotyping.
-
Phenothiazines Boost Macrophage Antibacterial Defense
2026-09-26
Qiu and colleagues report that phenothiazines strengthen macrophage antibacterial activity alongside increased reactive oxygen species, autophagy, and lysosomal activity. Inhibitor and scavenger experiments support roles for autophagy and ROS, while a perphenazine infection model provides an initial in vivo indication of benefit; the results position host-directed therapy as a research direction, not an established treatment.
-
Isochlorogenic Acid A Disrupts Multiple HBV Life-Cycle Steps
2026-09-25
The study finds that isochlorogenic acid A (ICAA) reduces HBV markers across several stages of the viral life cycle, alongside HO-1 upregulation and altered intracellular ROS. Its mechanistic contribution is to connect redox changes with viral particle assembly defects, while leaving open whether HO-1 catalytic activity directly causes each antiviral effect.
-
Cisapride and Deep Learning in Cardiac Safety
2026-09-25
Cisapride (R 51619) offers a useful way to examine how serotonergic signaling and hERG channel inhibition can complicate cardiac safety readouts. This article connects its dual pharmacology to deep-learning analysis of iPSC-derived cardiomyocytes, with an emphasis on interpreting phenotypes and choosing orthogonal validation.
-
Atrial Natriuretic Peptide: Practical Lab Workflows
2026-09-24
Turn ANP experiments into a structured workflow for vascular, renal, and metabolic assays, with practical controls for peptide handling and biological readouts. A key identity check helps distinguish the listed ANP 1-11 fragment from full-length hormone before interpreting activity.
-
Go 6983: From PKC Signaling to Striatal Behavior
2026-09-24
Go 6983 is a pan-PKC inhibitor for probing how protein kinase C signaling may shape neuronal excitability and repetitive behavior. This article connects recent striatal research to practical assay decisions while distinguishing a mechanistic hypothesis from evidence that the compound has been tested in that model.
-
MK-8745: Aurora A Inhibitor Workflows
2026-09-23
Use MK-8745 to connect Aurora A inhibition with mitotic arrest and apoptosis readouts, then test whether those responses depend on p53 status. A recent retinoblastoma study adds a distinct translational rationale for investigating AURKA, while not establishing MK-8745 as a validated treatment in that disease.
-
CD300LD-Targeted mRNA Nanovaccines in HCC
2026-09-23
The reference study develops a biomimetic mRNA nanovaccine that targets CD300LD-expressing tumor-associated neutrophils and delivers albumin-fused IL-36γ to reprogram their activity in hepatocellular carcinoma. Its preclinical findings indicate that selective neutrophil activation can strengthen antitumor immunity and improve survival, while also highlighting the need for careful validation of receptor specificity, formulation, and translational safety.
-
Intracellular Action of Bestatin and Actinonin
2026-09-22
Grujic and Renko showed that bestatin and actinonin inhibit proliferation of U937 and K562 cells mainly through intracellular activity rather than inhibition of cell-surface aminopeptidases. Efflux-modifier experiments further linked their activity to MRP- and, for bestatin in K562 cells, P-glycoprotein-dependent transport, providing a practical framework for interpreting intracellular drug accumulation.